The facility houses technology for Antibody Dependent Cell Cytotoxicity (ADCC), Complement Dependent Cytotoxicity (CDC) and Surface Plasmon Resonance (SPR) assays. It will also provide GMP-compliant in vitro and PCR-based assays for the detection of adventitious agents.
Plans for the laboratory were announced in 2014 a year after BioOutsource set up a sales office in the US.
SSB bought Glasgow, Scotland-based BioOutsource in April last, citing a desire to add contract testing services.
At the time the BioOutsource CEO Gerry Mackay hinted that being part of a larger organisation would allow the contract research organisation (CRO) to tap into demand in other markets, including the US.
He said: “As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing.”